supp.fit

Vitamin C, Copper, Zinc and Vitamin E: study protocols

15 study groups took Vitamin C together with Copper, Zinc and Vitamin E. These are the doses the studies gave. They are not a recommendation.

Vitamin C: what the research found →

Dose per serving from research: Vitamin C

15 study groups in 9 studies say how much Vitamin C participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 mg to 500 mg, 60% of 15 study groups.

Daily doseStudy groups
25 mg to 50 mg
3
50 mg to 100 mg
1
100 mg to 250 mg
2
250 mg to 500 mg
9

Dose per serving from research: Copper

9 study groups in 8 studies say how much Copper participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 mg to 2.5 mg, 67% of 9 study groups.

Daily doseStudy groups
250 mcg to 500 mcg
2
500 mcg to 1 mg
1
1 mg to 2.5 mg
6

Dose per serving from research: Zinc

15 study groups in 9 studies say how much Zinc participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 50 mg to 100 mg, 47% of 15 study groups.

Daily doseStudy groups
5 mg to 10 mg
2
10 mg to 25 mg
4
25 mg to 50 mg
2
50 mg to 100 mg
7

Dose per serving from research: Vitamin E

7 study groups in 3 studies say how much Vitamin E participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 IU to 500 IU, 100% of 7 study groups.

Daily doseStudy groups
250 IU to 500 IU
7

Commonly used together

13 of 15 study groups took Vitamin C, Copper, Zinc and Vitamin E with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Beta-Carotene
8
Iron
4
Vitamin A
4
Selenium
3

15 study groups

Study
Effects of fortified milk on morbidity in young children in north India: community based, randomised, double masked placebo controlled trial
2007 · fortified milk · Children aged 1–3 years in a peri-urban settlement in north India
40.2 mg270 mcg7.8 mg7.5 mg1 year316
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8
2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye
500 mg2 mg80 mg400 IU8 years—
Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren
2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified
50 mg2 mg20 mg8 mg335 days—
Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal
2003 · Multiple micronutrients · Pregnant women in rural Nepal
100 mg2 mg30 mg10 mg——
No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38
2014 · antioxidants plus zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years
500 mg2 mg80 mg400 IU9 years—
Micronutrient fortified milk improves iron status, anemia and growth among children 1-4 years: a double masked, randomized, controlled trial
2010 · Micronutrient-fortified milk (MN group) · Children aged 1–4 years in India; many had anemia, iron deficiency, or growth faltering
40.2 mg270 mcg7.8 mg7.5 mg1 year316
Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year
2008 · treated AMD (T-AMD) group · Patients with nonadvanced age-related macular degeneration; mean age 69.4 years
180 mg1 mg22.5 mg30 mg1 year15
Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study
2014 · softgel half-dose (single softgel) · Healthy adults aged 18–45 years, women and men
226 mg—34.8 mg—1 day15
Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study
2014 · softgel full-dose (two softgels) · Healthy adults aged 18–45 years, women and men
452 mg—69.6 mg—1 day15
Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study
2014 · tablet full-dose (four tablets) · Healthy adults aged 18–45 years, women and men
452 mg—69.6 mg400 mg1 day15
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration
500 mg2 mg80 mg400 IU5 years—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation
500 mg2 mg80 mg400 IU5 years—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 original AREDS formulation without β-carotene · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation
500 mg—80 mg400 IU5 years—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation
500 mg—25 mg400 IU5 years—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 original AREDS formulation without β-carotene and with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation
500 mg—25 mg400 IU5 years—